loading
Precedente Chiudi:
$19.65
Aprire:
$20.04
Volume 24 ore:
947.03K
Relative Volume:
2.31
Capitalizzazione di mercato:
$1.06B
Reddito:
-
Utile/perdita netta:
$-85.21M
Rapporto P/E:
-10.92
EPS:
-1.89
Flusso di cassa netto:
$-68.53M
1 W Prestazione:
-4.00%
1M Prestazione:
+7.84%
6M Prestazione:
-13.64%
1 anno Prestazione:
-4.88%
Intervallo 1D:
Value
$19.73
$21.29
Intervallo di 1 settimana:
Value
$19.22
$21.89
Portata 52W:
Value
$13.30
$30.03

Enliven Therapeutics Inc Stock (ELVN) Company Profile

Name
Nome
Enliven Therapeutics Inc
Name
Telefono
720-647-8519
Name
Indirizzo
6200 LOOKOUT ROAD, BOULDER
Name
Dipendente
65
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
ELVN's Discussions on Twitter

Confronta ELVN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ELVN
Enliven Therapeutics Inc
20.64 1.06B 0 -85.21M -68.53M -1.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-16 Iniziato Goldman Buy
2024-12-13 Iniziato BTIG Research Buy
2024-09-09 Iniziato H.C. Wainwright Buy
2024-06-11 Iniziato Robert W. Baird Outperform
2024-04-09 Iniziato Mizuho Buy
2023-03-29 Iniziato Jefferies Buy
Mostra tutto

Enliven Therapeutics Inc Borsa (ELVN) Ultime notizie

pulisher
Jun 18, 2025

Enliven Therapeutics CEO Kintz sells $277k in shares By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 17, 2025

Enliven grosses $230M from stock sale - BizWest

Jun 17, 2025
pulisher
Jun 17, 2025

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - Eastern Progress

Jun 17, 2025
pulisher
Jun 17, 2025

Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Enliven Raises $230m To Fund Scemblix Leukemia Challenger - insights.citeline.com

Jun 17, 2025
pulisher
Jun 17, 2025

Enliven Therapeutics (NASDAQ:ELVN) Given New $52.00 Price Target at Robert W. Baird - Defense World

Jun 17, 2025
pulisher
Jun 17, 2025

Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at The Goldman Sachs Group - Defense World

Jun 17, 2025
pulisher
Jun 17, 2025

Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up on Analyst Upgrade - Defense World

Jun 17, 2025
pulisher
Jun 16, 2025

10 Best NASDAQ Stocks Under $50 to Buy - Insider Monkey

Jun 16, 2025
pulisher
Jun 16, 2025

Enliven Therapeutics Closes Public Offering - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Biotech Enliven Therapeutics Secures Massive $230M Funding Through Oversubscribed Public Offering - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

Form 424B5 Enliven Therapeutics, - StreetInsider

Jun 16, 2025
pulisher
Jun 16, 2025

Enliven (ELVN) Gains Buy Rating from Goldman Sachs with $37 Price Target | ELVN Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 15, 2025

Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Down – Should You Sell? - Defense World

Jun 15, 2025
pulisher
Jun 14, 2025

Enliven (ELVN) Initiates $200M Public Stock Offering | ELVN Stoc - GuruFocus

Jun 14, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - The Malaysian Reserve

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics prices $200 million public offering By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Inc (ELVN) Stock: A Year of Highs and Lows in the Market - investchronicle.com

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven to sell $200M in stock after positive drug trial - BizWest

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Announces $200 Mln Offering Of Common Stock, Pre-Funded Warrants - Nasdaq

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics prices $200 million public offering - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Biotech Breakthrough: Enliven Therapeutics Secures Massive $200M Funding Backed by Goldman Sachs - Stock Titan

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Announces Proposed Public Offering Of Common Stock - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Announces Public Offering Of $200 Mln Of Shares - Nasdaq

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Launches $200 Million Securities Offering - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Announces Positive Phase 1 Trial Results - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics announces $200 million public offering - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

SEC Form 424B5 filed by Enliven Therapeutics Inc. - Quantisnow

Jun 13, 2025
pulisher
Jun 13, 2025

Biotech Enliven Therapeutics Unveils Massive $200M Stock Offering with Pre-Funded Warrants Option - Stock Titan

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress - PR Newswire

Jun 13, 2025
pulisher
Jun 12, 2025

California State Teachers Retirement System Buys 1,940 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $984,000 Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Two Sigma Investments LP Has $329,000 Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Bank of America Corp DE Sells 14,504 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Enliven Therapeutics (NASDAQ:ELVN) Shares Down 4% After Insider Selling - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Millennium Management LLC Buys 26,449 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

ELVN Stock Price and Chart — NASDAQ:ELVN - TradingView

Jun 04, 2025
pulisher
Jun 03, 2025

Ameriprise Financial Inc. Invests $789,000 in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

What is Lifesci Capital’s Forecast for ELVN FY2025 Earnings? - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

(ELVN) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jun 01, 2025
pulisher
Jun 01, 2025

BNP Paribas Financial Markets Purchases New Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

What is Lifesci Capital’s Forecast for ELVN Q2 Earnings? - Defense World

May 31, 2025
pulisher
May 30, 2025

Enliven Therapeutics (ELVN) Gets a Buy from Mizuho Securities - The Globe and Mail

May 30, 2025
pulisher
May 30, 2025

Mizuho Adjusts Price Target on Enliven Therapeutics to $41 From $39, Maintains Outperform Rating - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World

May 30, 2025
pulisher
May 28, 2025

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Increased by Deutsche Bank AG - Defense World

May 28, 2025
pulisher
May 25, 2025

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $37.25 Consensus PT from Analysts - Defense World

May 25, 2025
pulisher
May 22, 2025

Enliven Therapeutics to Present at Upcoming Investor Conferences - Nasdaq

May 22, 2025
pulisher
May 22, 2025

(ELVN) Proactive Strategies - news.stocktradersdaily.com

May 22, 2025
pulisher
May 22, 2025

Enliven Therapeutics chief scientific officer sells $81,533 in stock - Investing.com Australia

May 22, 2025
pulisher
May 21, 2025

Enliven Therapeutics chief scientific officer sells $81,533 in stock By Investing.com - Investing.com India

May 21, 2025

Enliven Therapeutics Inc Azioni (ELVN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Enliven Therapeutics Inc Azioni (ELVN) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Hohl Benjamin
CHIEF FINANCIAL OFFICER
Jun 27 '25
Sale
20.91
3,250
67,956
23,000
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):